In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP - Research Report), with a price target of $12.00. The company's shares opened today at $3.25.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -38.1% and a 14.47% success rate on recommended stocks. Acurx Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.See the top stocks recommended by analysts >>The company has a one-year high of $5.50 and a one-year low of $2.33.
https://www.tipranks.com/news/blurbs/maxim-group-reaffirms-their-buy-rating-on-acurx-pharmaceuticals-acxp?utm_source=advfn.com&utm_medium=referral
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Acurx Pharmaceuticals Charts.
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Acurx Pharmaceuticals Charts.